The anticancer activity of δ-tocotrienol and its oxazine derivatives were found to be associated with a reduction in PI3K/Akt/mTOR and/or MAPK activity in several types of tumor cells [23, 24]. The gene discussed is AKT1; the disease is neoplasm.